. 2018 Jan 4;8(1):94–109. doi: 10.1002/2211-5463.12354

Table 2.

Relationship between the expression of miR‐193a and clinicopathological features in LUSC from TCGA (mean ± SD). For RPKM, Student's paired or unpaired t test was used

Clinicopathological feature		n	miR‐193a relevant expression
Clinicopathological feature		n	RPKM (log2)	t	P
Tissue	Lung cancer	480	7.525952 ± 0.865471	−4.948157	0.000004
Tissue	Adjacent non‐cancerous lung	45	7.888973 ± 0.414712	−4.948157	0.000004
Age	> 65	185	7.525579 ± 0.934945	0.050481	0.959761
Age	≤ 65	289	7.521452 ± 0.823057	0.050481	0.959761
Gender	Male	347	7.558295 ± 0.865309	1.637792	0.102140
Gender	Female	121	7.408978 ± 0.858448	1.637792	0.102140
Smoker	Yes	130	7.656648 ± 0.790222	2.277028	0.023243
Smoker	No	332	7.454980 ± 0.880344	2.277028	0.023243
Clinical TNM stage	I and II	378	7.521731 ± 0.846972	0.254974	0.798856
Clinical TNM stage	III and IV	88	7.495593 ± 0.944560	0.254974	0.798856
T	T1 and T2	380	7.484478 ± 0.855391	−1.834394	0.067233
T	T3 and T4	88	7.671741 ± 0.894978	−1.834394	0.067233
N	Yes	167	7.421628 ± 0.937902	−1.652229	0.099505
N	No	295	7.565224 ± 0.821211	−1.652229	0.099505
M	Yes	6	8.014767 ± 0.412640	1.541487	0.124018
M	No	382	7.458407 ± 0.881689	1.541487	0.124018
Tumor diameter (cm)	> 0.9 cm	244	7.496234 ± 0.783197	−0.689266	0.491016
Tumor diameter (cm)	≤ 0.9 cm	230	7.551525 ± 0.949650	−0.689266	0.491016
Location	Central	136	7.585938 ± 0.831344	−0.437418	0.662227
Location	Peripheral	91	7.636411 ± 0.882065	−0.437418	0.662227
Residual tumor	Yes	14	7.627271 ± 0.597706	0.708142	0.479285
Residual tumor	No	374	7.455612 ± 0.898980	0.708142	0.479285
Neoadjuvant treatment	Yes	6	7.213383 ± 0.602037	−0.872681	0.383287
Neoadjuvant treatment	No	462	7.523668 ± 0.867740	−0.872681	0.383287
Radiation therapy	Yes	41	7.486063 ± 0.787671	−0.300110	0.764266
Radiation therapy	No	321	7.527955 ± 0.848168	−0.300110	0.764266
Targeted molecular therapy	Yes	113	7.451135 ± 0.797590	−0.998845	0.318533
Targeted molecular therapy	No	253	7.545861 ± 0.855592	−0.998845	0.318533